Thursday, April 14, 2022 1:06:14 PM
REDWOOD CITY, Calif., March 23, 2022 (GLOBE NEWSWIRE) -- Rezolute, Inc. (Nasdaq: RZLT), a clinical-stage biopharmaceutical company dedicated to developing transformative therapies with the potential to disrupt current treatment paradigms for devastating metabolic diseases, today announced positive data from its Phase 2b RIZE study of RZ358. The data demonstrated the safety and tolerability of RZ358 in patients with congenital hyperinsulinism, as well as highly significant improvements in hypoglycemia. The RIZE study results will be presented in an oral presentation at an upcoming medical congress in 2Q 2022, followed by a conference call hosted by the Company to discuss the data.
“We are very encouraged by the results and are looking forward to moving the program into Phase 3,” said Nevan Charles Elam, CEO and Founder of Rezolute. Mr. Elam continued, “We are very grateful to the patients, their families, patient advocacy organizations, and the investigators who participated in this study. I also appreciate the tremendous dedication of the Rezolute team, who are mission driven to develop an innovative treatment option for this debilitating condition.”
Recent RZLT News
- Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405] • Edgar (US Regulatory) • 09/19/2024 08:23:03 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 09/19/2024 08:09:55 PM
- Rezolute Reports Fourth Quarter and Full Year Fiscal 2024 Financial Results and Provides Business Update • GlobeNewswire Inc. • 09/19/2024 08:05:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 09/09/2024 11:30:26 AM
- FDA Lifts Partial Clinical Holds on RZ358 for the Treatment of Congenital Hyperinsulinism and Authorizes U.S. Inclusion in Ongoing Phase 3 Study • GlobeNewswire Inc. • 09/09/2024 11:30:00 AM
- Rezolute to Participate in Upcoming Investor Conferences • GlobeNewswire Inc. • 08/27/2024 12:00:00 PM
- Form EFFECT - Notice of Effectiveness • Edgar (US Regulatory) • 08/15/2024 04:15:11 AM
- Form S-3/A - Registration statement under Securities Act of 1933: [Amend] • Edgar (US Regulatory) • 08/10/2024 01:47:17 AM
- Form S-3 - Registration statement under Securities Act of 1933 • Edgar (US Regulatory) • 08/05/2024 09:00:55 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 08/05/2024 11:30:33 AM
- Rezolute Announces FDA Clearance of IND Application for Phase 3 Registrational Study of RZ358 for Treatment of Hypoglycemia Due to Tumor Hyperinsulinism • GlobeNewswire Inc. • 08/05/2024 11:30:00 AM
- Rezolute to Participate in the BTIG Virtual Biotechnology Conference • GlobeNewswire Inc. • 07/31/2024 12:00:00 PM
- Rezolute Announces Exercise of Underwriters’ Option to Purchase Additional Shares and Concurrent Private Placement • GlobeNewswire Inc. • 06/27/2024 12:00:00 PM
- Rezolute Announces Closing of Public Offering with Approximately $60M in Gross Proceeds • GlobeNewswire Inc. • 06/24/2024 12:00:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 06/14/2024 08:51:28 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 06/14/2024 08:49:30 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 06/14/2024 04:51:20 PM
- Rezolute Announces Pricing of Public Offering of $60 Million of Common Stock and Pre-Funded Warrants • GlobeNewswire Inc. • 06/14/2024 03:30:00 AM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 06/13/2024 09:25:55 PM
- Rezolute Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants • GlobeNewswire Inc. • 06/13/2024 08:01:00 PM
- Rezolute to Participate in the Jefferies Global Healthcare Conference • GlobeNewswire Inc. • 05/30/2024 12:00:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 05/28/2024 06:56:52 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/24/2024 06:37:52 PM
- Rezolute Reports Positive Topline Results from Phase 2 Proof of Concept Study of RZ402 in Patients with Diabetic Macular Edema (DME) • GlobeNewswire Inc. • 05/21/2024 08:05:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/17/2024 08:21:45 PM
VHAI - Vocodia Partners with Leading Political Super PACs to Revolutionize Fundraising Efforts • VHAI • Sep 19, 2024 11:48 AM
Dear Cashmere Group Holding Co. AKA Swifty Global Signs Binding Letter of Intent to be Acquired by Signing Day Sports • DRCR • Sep 19, 2024 10:26 AM
HealthLynked Launches Virtual Urgent Care Through Partnership with Lyric Health. • HLYK • Sep 19, 2024 8:00 AM
Element79 Gold Corp. Appoints Kevin Arias as Advisor to the Board of Directors, Strengthening Strategic Leadership • ELMGF • Sep 18, 2024 10:29 AM
Mawson Finland Limited Further Expands the Known Mineralized Zones at Rajapalot: Palokas step-out drills 7 metres @ 9.1 g/t gold & 706 ppm cobalt • MFL • Sep 17, 2024 9:02 AM
PickleJar Announces Integration With OptCulture to Deliver Holistic Fan Experiences at Venue Point of Sale • PKLE • Sep 17, 2024 8:00 AM